跳至主要内容
临床试验/NCT00418366
NCT00418366已完成1 期

An Open- Label, 2 Part Study to Investigate the Pharmacokinetics, Safety, and Tolerability of MK0431(Sitagliptin Phosphate) in Patients With Varying Degrees of Renal Insufficiency

Merck Sharp & Dohme LLC0 个研究点目标入组 24 人开始时间: 2003年1月1日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
24
主要终点
Determination of the pharmacokinetics of MK0431 (sitagliptin phosphate) in patients with renal insufficiency compared to healthy volunteers

研究概览

简要总结

A study to evaluate the effect of kidney disease, from mild to severe disease, on a diabetes medication

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Male and non-pregnant females with a clinical diagnosis of renal insufficiency with mild, moderate, severe or end stage renal disease on hemodialysis
  • •A body mass index of less than 40 kg per meter squared (body weight in kg divided by height in meters squared)
  • •Smokes less than 10 cigarettes/day

排除标准

  • •Patients with uncontrolled diabetes or uncontrolled congestive heart failure
  • •Patient has abnormal prestudy laboratory measurements including serum potassium or white blood counts
  • •Patient has systolic blood pressure below 100 mm Hg or above 180 mm Hg
  • •Patient has diastolic blood pressure less than 50 mm Hg systolic or above 100 mmHg

结局指标

主要结局

Determination of the pharmacokinetics of MK0431 (sitagliptin phosphate) in patients with renal insufficiency compared to healthy volunteers

次要结局

  • Safety and tolerability in patients with renal insufficiency

研究者

申办方类型
Industry
责任方
Sponsor

相似试验